27 / 84
267
Ces Urol 2015; 19(4): 256–269
PŘEHLEDOVÝ ČLÁNEK
4. Kuban DA, Levy LB, Cheung MR, et al.
Long-term failure patterns and survival in a randomized dose‑
-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. United States: 2011
Elsevier Inc; 2011. p. 1310–1317.
5.
http://www.uroweb.cz/index.php?pg=dg--nadory-prostaty--projekty--analyzydostupnychpopulacni‑
chdat-a-predikce-pro-obdobi-let-2011–2015-zhoubny-nador-prostaty--vysledky-analyzpopulacnichdat‑
-pro-karcinom-prostaty. Accesed May 25
th
, 2015.
6. Mottet N BJ, Briers E, Briers E, et al.
Guidelines on Prostate Cancer. Arnhem, The Netherlands. Edition
presented at the EAU Annual Congress Madrid 2015.
7. Heidenreich A, Bastian PJ, Bellmunt J, et al.
EAU guidelines on prostate cancer. Part II: Treatment of
advanced, relapsing, and castration resistant prostate cancer. Eur Urol 2014; 65(2): 467–479.
8. Cooperberg MR, Carroll PR, Klotz L.
Active surveillance for prostate cancer: progress and promise.
J Clin Oncol 2011; 3669–3676.
9. Vickers A BC, Steineck G, et al.
Individualized estimation of the benefit of radical prostatectomy from
the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012; 62(2): 204–209.
10. van den Bergh RC, Roemeling S, Roobol MJ, et al.
Outcomes of men with screen-detected prostate
cancer eligible for active surveillance who were managed expectantly. Eur Urol; 2009. 1–8.
11. Porter CR, Gallina A, Kodama K, et al.
Prostate cancer-specific survival in men treated with hormonal
therapy after failure of radical prostatectomy. Eur Urol 2007; 446–452.
12. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL.
Impact of comorbidity on survival among
men with localized prostate cancer. J Clin Oncol 2011; 29(10): 1335–1341.
13. Holmberg L, Bill-Axelson A, Steineck G, et al.
Results from the Scandinavian Prostate Cancer Group
Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting. J Natl Cancer
Inst Monogr. 2012 Dec; 2012(45): 230–233.
14. Wilt TJ, Brawer MK, Jones KM, et al.
Radical prostatectomy versus observation for localized prostate
cancer. N Engl J Med. 2012; 367(3): 203–213.
15. Briganti A, Larcher A, Abdollah F, et al.
Updated Nomogram Predicting Lymph Node Invasion in Pati‑
ents with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance
of Percentage of Positive Cores. Eur Urol 2012; 61(3): 480–487.
16. Joniau S, Spahn M, Briganti A, et al.
Pretreatment Tables Predicting Pathologic Stage of Locally
Advanced Prostate Cancer. Eur Urol 2015; 67(2): 319–325.
17. Messing EM, Manola J, Yao J, et al.
Immediate versus deferred androgen deprivation treatment in
patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Lancet Oncol 2006; 7(6): 472–479.
18. Engel J, Bastian PJ, Baur H, et al.
Survival benefit of radical prostatectomy in lymph node-positive
patients with prostate cancer. Eur Urol 2010; 57(5): 754–761.
19. Seiler R, Studer UE, Tschan K, et al.
Removal of limited nodal disease in patients undergoing radical
prostatectomy: long-term results confirm a chance for cure. J Urol 2014; 191(5): 1280–1285.
20. Gandaglia G, Sammon JD, Chang SL, et al.
Comparative Effectiveness of Robot-Assisted and Open
Radical Prostatectomy in the Postdissemination Era. J Clin Oncol 2014; doi: 10.1200/JCO.2013.53.5096.
21. Kang DC, Hardee MJ, Fesperman SF, et al.
Low quality of evidence for robot-assisted laparoscopic
prostatectomy: results of a systematic review of the published literature. Eur Urol 2010; 57(6): 930–937.
22. Sammon JD, Abdollah F, Klett DE, et al.
The diminishing returns of robotic diffusion: complications
following robot-assisted radical prostatectomy. BJU Int 2015; Mar 6.
23. Montorsi F, Wilson TG, Rosen RC, et al.
Best practices in robot-assisted radical prostatectomy: reco‑
mmendations of the Pasadena Consensus Panel. Eur Urol 2012; 62(3): 368–381.